China-based drug maker Innovent Biologics has revealed that China’s National Medical Products Administration has approved its application to test a combination therapy comprising a proposed biosimilar bevacizumab product, IBI305, plus sintilimab, an anti–programmed cell death protein 1 (PD-1) monoclonal antibody.
China-based drug maker Innovent Biologics has revealed that China’s National Medical Products Administration has approved its application to test a combination therapy comprising a proposed biosimilar bevacizumab product, IBI305, plus sintilimab, an anti—programmed cell death protein 1 (PD-1) monoclonal antibody.
Innovent’s clinical trials for the combination will include patients with non—small cell lung cancer (NSCLC) and hepatocellular carcinoma.
According to Innovent, the relationship between vascular endothelial growth factor—targeted by bevacizumab—and tumor-induced immunosuppression driven by PD-1 is a promising target. Abnormal tumor-induced angiogenesis appears to limit the therapeutic effect of anti—PD-1 antibodies and other immunotherapy products, and Innovent hopes the combination of sintilimab and biosimilarbevacizumab will be better able to control tumor growth by stimulating the immune system with an anti–PD-1 agent and blocking angiogenesis with bevacizumab.
Innovent says that has completed bioequivalence studies for IBI305 in healthy volunteers, as well as a randomized, double-blind, multicenter phase 3 study in patients with NSCLC. The phase 3 study compared IBI305 with the reference Avastin.
Sintilimab, which Innovent has developed jointly with Eli Lilly, has already shown promising results as a first-line treatment for patients with NSCLC; in September 2018, Innovent presented data on sintilimab in combination with pemetrexed and cisplatin in patients with nonsquamous NSCLC during the annual meeting of the Chinese Society of Clinical Oncology. The combination, said Innovent’s researchers, demonstrated and objective response rate of 68.4%, based on 19 patients.
"It was encouraging to learn the outstanding efficacy of sintilimab in combination with pemetrexed and cisplatin for first line treatment of NSCLC. I hope to see the approval of sintilimab for first-line treatment of NSCLC in the near future, allowing more patients suffering from NSCLC to benefit from it," Caicun Zhou, MD, PhD, of the Shanghai Pulmonary Hospital, said in a statement.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.
Bevacizumab Biosimilars Offer Promise for CRC Treatment, Wound Healing, and Cost Savings
February 28th 2024A review emphasizes that bevacizumab biosimilars demonstrate comparable efficacy to the reference product (Avastin) in the treatment of colorectal cancer (CRC) by tackling wound healing concerns in anorectal medicine.